Issue Date: November 29, 2010
Mismatch Route To Targeted Therapy
A new therapeutic strategy for treating Huntington’s disease patients that is based on small interfering RNA (siRNA) could have fewer side effects than earlier approaches (Chem. Biol., DOI: 10.1016/j.chembiol.2010.10.013). The technique uses designed synthetic RNAs that behave counterintuitively: They work better when modified to interact less efficiently with their intended targets.
If it can be replicated in vivo, the work could lead to therapies for Huntington’s disease and similar conditions that result from genetic mutations . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society